Amerise Biosciences Ltd Stock Price Today (NSE: AMERISE)
Fundamental Score
Amerise Biosciences Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Amerise Biosciences Ltd share price today is ₹0.69, up +0.00% on NSE/BSE as of 18 March 2026. Amerise Biosciences Ltd (AMERISE) is a Small-cap company in the Plastic Products - Industrial sector with a market capitalisation of ₹3.97 (Cr). The 52-week high for AMERISE share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 99.19x, AMERISE is currently trading above its industry average P/E of 23.37x. The company has a Return on Equity (ROE) of 0.19% and a debt-to-equity ratio of 0.00.
Amerise Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Amerise Biosciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Stability Analysis of Amerise Biosciences Share Price
The industrial plastic products sector is currently experiencing heightened volatility due to fluctuating raw material costs and evolving environmental regulations, factors impacting profitability and investment decisions. This analysis examines the financial stability of Amerise Biosciences Ltd, focusing on its current share price and key performance indicators. The current Amerise Biosciences share price is ₹0.7599999904632568. Considering this price point, a deeper dive into the company's financials is warranted to ascertain its investment viability.
A critical metric is the Price-to-Earnings (PE) ratio, which currently stands at 99.19 for Amerise Biosciences. This suggests that investors are paying a significant premium for each rupee of earnings, possibly reflecting high growth expectations. However, when compared to peers, a high PE ratio can also indicate potential overvaluation. While we are not directly evaluating
B D Industries here, it is worth considering their management quality, operational efficiencies, and debt management compared to Amerise Biosciences to understand the rationale behind the PE difference. A comprehensive assessment would involve analyzing management's strategic vision and execution capabilities, a factor that influences investor confidence.Another key indicator is the Return on Capital Employed (ROCE) of 0.19%. This is a significantly low ROCE, indicating that the company is not efficiently generating profits from its capital investments. This limited return severely impacts the company's ability to build a strong economic moat. A low ROCE may deter further investment, restrict internal funding for research and development, and weaken its competitive advantage in the long term.
It's important to note that this is a preliminary financial analysis of Amerise Biosciences share price, derived from publicly available data and focusing on a few key parameters. A more comprehensive evaluation would require a deep dive into the company's balance sheet, cash flow statement, and detailed industry analysis. This analysis forms part of a larger 80-parameter fundamental audit verified by Sweta Mishra and should not be interpreted as investment advice. Further due diligence is highly recommended before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Amerise Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AMERISE across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Excellent EPS Growth (15.63% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (15.63% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (0.19%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.19%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 99.19x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-33.33%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Amerise Biosciences Ltd Financial Statements
Comprehensive financial data for Amerise Biosciences Ltd including income statement, balance sheet and cash flow
About AMERISE (Amerise Biosciences Ltd)
Amerise Biosciences Ltd (AMERISE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Plastic Products - Industrial sector with a current market capitalisation of ₹3.97 (Cr). Amerise Biosciences Ltd has delivered a Return on Equity (ROE) of 0.19% and a ROCE of 0.19%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking AMERISE share price can monitor key metrics including P/E ratio, promoter holding of 0.00%, and quarterly earnings growth.
Company Details
Key Leadership
Latest News
AMERISE Share Price: Frequently Asked Questions
What is the current share price of Amerise Biosciences Ltd (AMERISE)?
As of 18 Mar 2026, 10:12 am IST, Amerise Biosciences Ltd share price is ₹0.69. The AMERISE stock has a market capitalisation of ₹3.97 (Cr) on NSE/BSE.
Is AMERISE share price Overvalued or Undervalued?
AMERISE share price is currently trading at a P/E ratio of 99.19x, compared to the industry average of 23.37x. Based on this relative valuation, the Amerise Biosciences Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of AMERISE share price?
The 52-week high of AMERISE share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Amerise Biosciences Ltd share price?
Key factors influencing AMERISE share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Amerise Biosciences Ltd a good stock for long-term investment?
Amerise Biosciences Ltd shows a 5-year Profit Growth of 15.63% and an ROE of 0.19%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in AMERISE shares.
How does Amerise Biosciences Ltd compare with its industry peers?
Amerise Biosciences Ltd competes with major peers in the Plastic Products - Industrial. Investors should compare AMERISE share price P/E of 99.19x and ROE of 0.19% against the industry averages to determine competitive standing.
What is the P/E ratio of AMERISE and what does it mean?
AMERISE share price has a P/E ratio of 99.19x compared to the industry average of 23.37x. Investors pay ₹99 for every ₹1 of annual earnings.
How is AMERISE performing according to Bull Run's analysis?
AMERISE has a Bull Run fundamental score of 9.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AMERISE belong to?
AMERISE operates in the Plastic Products - Industrial industry. This classification helps understand the competitive landscape and sector-specific trends affecting Amerise Biosciences Ltd share price.
What is Return on Equity (ROE) and why is it important for AMERISE?
AMERISE has an ROE of 0.19%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Amerise Biosciences Ltd generates profits from shareholders capital.
How is AMERISE debt-to-equity ratio and what does it indicate?
AMERISE has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is AMERISE dividend yield and is it a good dividend stock?
AMERISE offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Amerise Biosciences Ltd shares.
How has AMERISE share price grown over the past 5 years?
AMERISE has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth 15.63%, and EPS Growth 15.63%.
What is the promoter holding in AMERISE and why does it matter?
Promoters hold 0.00% of AMERISE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Amerise Biosciences Ltd.
What is AMERISE market capitalisation category?
AMERISE has a market capitalisation of ₹4 crores, placing it in the Small-cap category.
How volatile is AMERISE stock?
AMERISE has a beta of N/A. A beta > 1 suggests the Amerise Biosciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AMERISE operating profit margin trend?
AMERISE has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is AMERISE quarterly performance?
Recent quarterly performance shows Amerise Biosciences Ltd YoY Sales Growth of N/A% and YoY Profit Growth of -33.33%.
What is the institutional holding pattern in AMERISE?
AMERISE has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Amerise Biosciences Ltd stock.